Comparative Pharmacology
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus NAPRELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus NAPRELAN.
MECLOFENAMATE SODIUM vs NAPRELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
750 mg to 1000 mg orally once daily, with or without food.
None Documented
None Documented
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Category C
Category C
NSAID
NSAID